Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vectura Prevails In US Litigation Over GSK’s Ellipta

Executive Summary

Vectura has won an award of almost $90m after convincing a Delaware jury that GSK’s Ellipta respiratory range infringed one of its US patents. The firm currently has a development deal with Hikma for generic versions.

You may also be interested in...



Vectura Agrees £958m Takeover Following Hikma Advair Launch

Weeks after partner Hikma launched its generic version of GSK’s Advair, Wiltshire-based Vectura has agreed a takeover offer by private equity Carlyle, which aims to build a market leading inhalation specialist CDMO.

Hikma and Vectura ally on Ellipta rivals

Hikma has announced a global development and marketing collaboration deal with Vectura aimed at developing generic versions of GlaxoSmlithKline’s (GSK’s) Ellipta respiratory portfolio. The agreement on rivals to Ellipta – which builds on an existing collaboration between the two firms to develop a generic version of GSK’s Advair Diskus (fluticasone/salmeterol) – will use Vectura’s proprietary ‘open-inhale-close’ dry-powder inhaler device.

Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB140306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel